Tessa E H Römkens1, Kim Gijsbers2, Wietske Kievit3, Frank Hoentjen2, Joost P H Drenth2. 1. Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Centre, Nijmegen; Department of Gastroenterology and Hepatology, Jeroen Bosch Hospital, 's Hertogenbosch, The Netherlands. tessa.romkens@radboudumc.nl. 2. Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. 3. Radboud university medical center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
Abstract
BACKGROUND AND AIMS: Recently, treatment goals in inflammatory bowel disease (IBD) in clinical trials have shifted from mainly symptom-based to more mucosa-driven. Real world data on treatment priorities are lacking. We aimed to investigate the current practice and most commonly used definitions of IBD treatment targets among Dutch gastroenterologists. METHODS: Dutch gastroenterologists were asked to participate in a computer-based nation-wide survey. We asked questions on demographics, opinion and current practice regarding IBD treatment targets. RESULTS: Twenty-four percent (134/556) of the respondents completed the survey. For both Crohn's disease (CD) (47.3%, 61/129) and ulcerative colitis (UC)(45%, 58/129) the main treatment goal was to achieve and maintain deep remission, defined as clinical, biochemical and endoscopic remission. Seventy-six percent of the participants use mucosal healing (MH) as a potential treatment target for IBD, whereas 22.6% use histological remission. There is no single definition for MH in IBD. The majority use Mayo score ≤ 1 in UC (52%) and 'macroscopic normal mucosa' in CD (66%). CONCLUSION: More stringent and mucosa-driven treatment targets as 'deep remission' and 'mucosal healing' have found traction in clinical practice. The most commonly used definition for MH in routine practice is endoscopic MAYO score </= 1 in UC and 'macroscopic normal mucosa' in CD.
BACKGROUND AND AIMS: Recently, treatment goals in inflammatory bowel disease (IBD) in clinical trials have shifted from mainly symptom-based to more mucosa-driven. Real world data on treatment priorities are lacking. We aimed to investigate the current practice and most commonly used definitions of IBD treatment targets among Dutch gastroenterologists. METHODS: Dutch gastroenterologists were asked to participate in a computer-based nation-wide survey. We asked questions on demographics, opinion and current practice regarding IBD treatment targets. RESULTS: Twenty-four percent (134/556) of the respondents completed the survey. For both Crohn's disease (CD) (47.3%, 61/129) and ulcerative colitis (UC)(45%, 58/129) the main treatment goal was to achieve and maintain deep remission, defined as clinical, biochemical and endoscopic remission. Seventy-six percent of the participants use mucosal healing (MH) as a potential treatment target for IBD, whereas 22.6% use histological remission. There is no single definition for MH in IBD. The majority use Mayo score ≤ 1 in UC (52%) and 'macroscopic normal mucosa' in CD (66%). CONCLUSION: More stringent and mucosa-driven treatment targets as 'deep remission' and 'mucosal healing' have found traction in clinical practice. The most commonly used definition for MH in routine practice is endoscopic MAYO score </= 1 in UC and 'macroscopic normal mucosa' in CD.
Authors: Philipp A Reuken; Philip C Grunert; Andreas Lügering; Niels Teich; Andreas Stallmach Journal: Therap Adv Gastroenterol Date: 2020-11-11 Impact factor: 4.409
Authors: Renske Wilhelmina Maria Pauwels; Annemarie Charlotte de Vries; Christien Janneke van der Woude Journal: J Gastroenterol Hepatol Date: 2020-05-04 Impact factor: 4.029